Endocrinology · Type 1 DiabetesTrial Updateclinicalmid-term

MyDiaMate Study Aims to Alleviate Diabetes Distress in Type 1 Diabetes

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:30:51 PM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The MyREMEDY study aims to evaluate a digital therapeutic solution for mental health in type 1 diabetes, which could reshape treatment approaches in this area. Success in this trial may accelerate the adoption of digital health solutions, impacting traditional diabetes management strategies. Regulatory context from FDA (FDA AP — CARBIDOPA AND LEVODOPA (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).

Strategic Assessment

If successful, this could lead to increased adoption of digital therapeutics in diabetes care, impacting traditional treatment paradigms. The strongest clinical anchor is MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY) (ClinicalTrials.gov), entity match (juvenile diabetes research foundation). In Endocrinology · Type 1 Diabetes, 8 regulatory and 2 competitive items passed relevance filtering for type 1 diabetes patients.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Study Reveals GES Variants Impact Resistance to Ceftazidime-Avibactam and Imipenem-Relebactam. This study could influence the development of digital health solutions targeting mental health in chronic conditions, particularly in diabetes management.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CARBIDOPA AND LEVODOPA (SUPPL) (FDA). Regulatory pathway relevance (nda). The outcomes of this study could lead to new regulatory considerations for digital therapeutics in diabetes care, potentially affecting approval processes and compliance requirements.

Key Risks

Elevated medium regulatory exposure for type 1 diabetes patients could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the MyDiaMate app proves effective, it could capture a significant share of the diabetes management market, driving revenue growth for digital health solutions. This may also influence partnerships and collaborations in the sector.
Upside for type 1 diabetes patients may improve if Development and Validation of Machine Learning Model for Differentiating Diabetic Kidney Disease and Non-Diabetic Kidney Disease in Type 2 Diabetes (ClinicalTrials.gov) delivers favorable follow-through.
Upside for type 1 diabetes patients may improve if Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
If successful, this could lead to increased adoption of digital therapeutics in diabetes care, impacting traditional treatment paradigms.

What Would Change This Assessment

This becomes more urgent if Monitor results from the MyREMEDY study and any subsequent partnerships or product launches related to MyDiaMate.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CARBIDOPA AND LEVODOPA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY)
ClinicalTrials.govhigh relevance
Entity match (juvenile diabetes research foundation)
FDA document
View source
Cardiometabolic Impact of Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Development and Validation of Machine Learning Model for Differentiating Diabetic Kidney Disease and Non-Diabetic Kidney Disease in Type 2 Diabetes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Study Reveals GES Variants Impact Resistance to Ceftazidime-Avibactam and Imipenem-Relebactam
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

type 1 diabetes patients
Juvenile Diabetes Research Foundation
Forschungsinstitut der Diabetes Akademie Mergentheim

Commercial impact

medium

If the MyDiaMate app proves effective, it could capture a significant share of the diabetes management market, driving revenue growth for digital health solutions. This may also influence partnerships and collaborations in the sector.

Regulatory impact

medium

The outcomes of this study could lead to new regulatory considerations for digital therapeutics in diabetes care, potentially affecting approval processes and compliance requirements.

What to watch

Monitor results from the MyREMEDY study and any subsequent partnerships or product launches related to MyDiaMate.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.